Palisade Bio to Present at Two Key Investor Conferences in March 2026
Event summary
- Palisade Bio will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, and hold investor meetings at the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026.
- The company's lead program, PALI-2108, achieved a 100% clinical response in a Phase 1b trial for ulcerative colitis (UC) with no serious adverse events.
- Palisade Bio is advancing towards a Phase 2 clinical study in UC and completing early studies in fibrostenotic Crohn’s disease.
The big picture
Palisade Bio’s participation in high-profile investor conferences underscores its push to engage with the investment community amid critical clinical milestones. The company’s differentiated prodrug platform and targeted approach to inflammatory and fibrotic diseases position it within a competitive landscape of biopharmaceutical firms aiming to improve treatment options for chronic conditions. The success of its lead program, PALI-2108, will be a key indicator of its ability to translate early-phase promise into commercial viability.
What we're watching
- Clinical Development
- The pace at which Palisade Bio advances its Phase 2 clinical study in UC and the results of its early studies in fibrostenotic Crohn’s disease will be critical to watch.
- Investor Sentiment
- How the market reacts to Palisade Bio’s presentations and investor meetings at the upcoming conferences could signal confidence in its pipeline.
- Regulatory Pathway
- Whether Palisade Bio can maintain its favorable safety and efficacy profile in larger clinical trials will be key to its regulatory strategy.
Related topics